Celecoxib and CVS risk--lessons from the APC and PreSAP studies.
Armstrong
D J
DJ
D000236:Adenoma / Q000517:prevention & control; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000517:prevention & control; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib